Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Nefecon Retreatment in IgA Nephropathy (NEF-301 Completers)
2020-003308-14Phase 3Completed
- Sponsor
- Calliditas Therapeutics AB
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nefecon in IgA nephropathy (IgAN), sponsored by Calliditas Therapeutics AB. Primary endpoint: eGFR ratio at 9 months vs baseline. Started Sep 2020; status: completed.
02
Drugs
nefecon
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2020-003308-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003308-14.